Venous Thromboembolism | Disease Landscape and Forecast | G7 | 2017
Venous thromboembolism ( VTE ), comprising deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ), represents a significant public health and financial burden. The launch of non-vitamin K antagonist oral anticoagulants ( NOAC s) for VTE is addressing the need for more-convenient alternatives compared with long-established therapies, and these agents will drive market growth in the near to mid term. Toward the end of our forecast period, generic NOAC s will be widely available, and the VTE market will enter a new phase of evolution. There are still considerable areas of unmet need within VTE , such as the primary prophylaxis of VTE in acute medically ill patients and ambulatory cancer patients. The ongoing label expansion program for the NOAC s and emerging therapies such as betrixaban and IONIS-FXIRx offer potential solutions to these unmet needs.
